Aktienanalyse zu Crinetics Pharmaceuticals Inc (CRNX)CRNXCrinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Crinetics Pharmaceuticals (CRNX) is currently trading at $84.84, very close to the analyst price target of $85. The RSI is at 82.058, indicating that the stock is overbought, which suggests caution for new buyers. The stock has shown a strong year-to-date change of +81.55% and a one-year change of +154.77%, reflecting significant growth. However, the forward P/E ratio is 0, indicating no earnings are expected in the near term, which is a risk for long-term investors. Given these factors, it's advisable to hold rather than buy at this moment, as the stock is near its acquisition price with limited upside potential.

3 analysts cover CRNX: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 89.40.